IN2012DN00928A - - Google Patents

Info

Publication number
IN2012DN00928A
IN2012DN00928A IN928DEN2012A IN2012DN00928A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A IN 928DEN2012 A IN928DEN2012 A IN 928DEN2012A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A
Authority
IN
India
Prior art keywords
treatment
relates
benzylideneaminoguanidines
dimethoxybenzylideneamino
guanidine
Prior art date
Application number
Other languages
English (en)
Inventor
Niklas Palmqvist
Anders Sjodin
Christina Wenglen
Christofer Flood
Lennart Lundberg
Elisabeth Seifert
Per Lek
Arne Boman
Original Assignee
Anamar Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0913427A external-priority patent/GB0913427D0/en
Priority claimed from GBGB1005495.5A external-priority patent/GB201005495D0/en
Priority claimed from GBGB1010671.4A external-priority patent/GB201010671D0/en
Application filed by Anamar Ab filed Critical Anamar Ab
Publication of IN2012DN00928A publication Critical patent/IN2012DN00928A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN928DEN2012 2009-07-31 2010-07-30 IN2012DN00928A (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0913427A GB0913427D0 (en) 2009-07-31 2009-07-31 Compounds for treatment of imflammation
GBGB1005495.5A GB201005495D0 (en) 2010-03-31 2010-03-31 Compounds for treatment of inflammation
GBGB1010671.4A GB201010671D0 (en) 2010-06-24 2010-06-24 Compounds for treatment of inflammation
PCT/GB2010/001457 WO2011012868A1 (en) 2009-07-31 2010-07-30 Compounds for treatment of inflammation

Publications (1)

Publication Number Publication Date
IN2012DN00928A true IN2012DN00928A (da) 2015-04-03

Family

ID=42799430

Family Applications (1)

Application Number Title Priority Date Filing Date
IN928DEN2012 IN2012DN00928A (da) 2009-07-31 2010-07-30

Country Status (13)

Country Link
US (1) US20120190751A1 (da)
EP (1) EP2470270A1 (da)
JP (1) JP2013500957A (da)
CN (1) CN102573993A (da)
AU (1) AU2010277356A1 (da)
BR (1) BR112012002267A2 (da)
CA (1) CA2769541A1 (da)
GB (1) GB2473095A (da)
IN (1) IN2012DN00928A (da)
MX (1) MX2012001144A (da)
NZ (1) NZ598124A (da)
RU (1) RU2012106467A (da)
WO (1) WO2011012868A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3109237A1 (en) 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN105561313B (zh) * 2016-01-25 2018-12-25 北京大学 降低5-ht2br含量和抑制其活性的物质在制备治疗和预防动脉粥样硬化产品中的应用
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
EP3790539A1 (en) * 2018-05-09 2021-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171067T1 (de) * 1990-03-16 1998-10-15 Beth Israel Hospital Verwendung von spiperon als immunsuppressivum und antiinflammatorisches mittel
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
EP0711553A1 (en) * 1994-08-09 1996-05-15 Mario Cagnoni Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis
AU7802700A (en) * 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US7060711B2 (en) * 2001-10-25 2006-06-13 Biofrontera Bioscience Gmbh Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
MXPA06003276A (es) * 2003-09-25 2006-06-08 Acadia Pharm Inc Tratamiento de dolor neuropatico con agonistas de receptor de neuropeptido ff 2.
GB0623381D0 (en) * 2006-11-23 2007-01-03 Acure Pharma Ab Use of a compound as VEGF inhibitor
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
GB0715048D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel compounds
US20120108668A1 (en) * 2009-03-24 2012-05-03 Lundstedt Erik Torbjoern Metabolic profiles

Also Published As

Publication number Publication date
AU2010277356A1 (en) 2012-03-08
EP2470270A1 (en) 2012-07-04
NZ598124A (en) 2014-01-31
US20120190751A1 (en) 2012-07-26
JP2013500957A (ja) 2013-01-10
CA2769541A1 (en) 2011-02-03
WO2011012868A1 (en) 2011-02-03
GB201012926D0 (en) 2010-09-15
CN102573993A (zh) 2012-07-11
RU2012106467A (ru) 2013-09-10
BR112012002267A2 (pt) 2016-11-08
MX2012001144A (es) 2012-05-08
GB2473095A (en) 2011-03-02

Similar Documents

Publication Publication Date Title
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
PH12014501736B1 (en) Therapeutic use of p75ntr neurotrophin binding protein
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2011007930A (es) Conjugados de insulina cristalina.
TN2012000302A1 (en) Oxyntomodulin peptide analogue
MX351083B (es) Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales.
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
MY155340A (en) Use of cathepsin c
IN2012DN00928A (da)
TR200909786A1 (tr) Sefiksim içeren efervesan tablet ve granül formülasyonu.
HK1141436A1 (en) Axomadol for treating pain from arthritis
HUE047515T2 (hu) N-Szubsztituált benzolpropánamidok fájdalom és gyulladás kezelésében történõ alkalmazásra
IL223065A0 (en) New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
MY179784A (en) Use of cathepsin h
WO2011067189A3 (de) Cmet-inhibitoren zur behandlung der endometriose
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
UA45304U (ru) Способ оценки состояния больного ревматоидным артритом и эффективности его лечения
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування
UA50825U (ru) Применение антагониста рецепторов интерлейкина-1 в качестве средства гипоурикемического действия
UA106224C2 (en) Crystalline insulin-conjugates